METHODS: First of all, we inoculated BALB/c nude mice with a subcutaneous injection of human A549 cells to generate our animal model. Mice were randomly divided into 3 groups and treated with normal saline (NS), CQ (25 mg/kg/3 days) or Bevacizumab (BE) (5 mg/kg/3 days). Tumor growth of the mice and microvascular density (MVD) were monitored. And we explored the effect of CQ on the proliferation, survive and proangiogenic signaling of tumor cells in vitro. We further evaluated the effect of CQ on human umbilical vein endothelial cells (HUVECs) viability, migration and tube formation. Chicken chorioallantoic membrane (CAM) Model was carried out to elucidate its effect on angiogenesis. By western blot, we analyzed the expression of Jagged1, Ang2 and LC3I/II in HUVECs treated by CQ. At the end, we established an MPE mice model by injecting Lewis lung carcinoma cells (LLCs) into pleural cavity of mice. CQ (25 mg/kg), BE (5 mg/kg) or normal saline was respectively injected into pleural cavity three times with 3-day interval in each group. The volume of pleural effusion, tumor foci, MVD were evaluated 21 days after the injection of LLCs.